Red Light Holland - Director and CEO, Todd Shapiro (Right).
Director and CEO, Todd Shapiro (Right).
Source: Daily Hive.
  • Red Light Holland (TRIP) has started growing its second crop of approximately 1 million grams of magic truffles
  • The truffles consist of three different strains, including Psilocybe Mexicana, Psilocybe Galindoi and Psilocybe Tampanensis
  • Red Light Holland’s growth operation, production and distribution facility is in Horst, The Netherlands
  • The batch is expected to be available in The Netherlands by mid-2021
  • Red Light Holland is up 1.11  per cent at C$0.45 per share

Red Light Holland (TRIP) has started growing its second crop of approximately 1 million grams of magic truffles.

The truffles consist of three different strains, including Psilocybe Mexicana, Psilocybe Galindoi and Psilocybe Tampanensis.

Red Light Holland is an Ontario-based company focused on the production, growth and sale of magic truffles to the legal market within The Netherlands.

Red Light Holland CEO and Director Todd Shapiro said this batch is expected to be 10 times the size of the original batch.

“We are proud as a company, in the Psychedelic sector to actually produce product now, as opposed to making mere projections about the future. We believe in providing responsible adult access now, through education and information and we are happy to be moving so quickly and efficiently,” he added.

Shapiro said Red Light Holland is almost done harvesting its first batch which has been pre-sold. Red Light Holland’s growth operation, production and distribution facility is in Horst, The Netherlands.

The expected batch is expected to be available in The Netherlands by mid-2021.

Red Light Holland is up 1.11 per cent at C$0.45 per share.

More From The Market Online
labratory work

PharmaTher locks in FDA-assigned goal date of abbreviated NDA

PharmaTher Holdings (CSE:PHRM) locks in its U.S. FDA-assigned goal date of abbreviated new drug application for Oct. 29, 2024.

Optimi Health makes first international MDMA shipment

Optimi Health (CSE:OPTI) makes its first international shipment of MDMA to The Institute for Psychedelic Research at Tel Aviv University.

Oncolytics Biotech approved to expand pancreatic cancer program

Oncolytics Biotech (TSX:ONC), a cancer immunotherapy stock, receives ethics and German regulatory approvals for a new pancreatic cancer study.